Ugradnja filtra u donju šuplju venu prije operacijskog zahvata u žene s tumorom jajnika i simptomima duboke venske tromboze: prikaz slučaja i pregled literature by Višnja Nesek Adam et al.
Acta Clin Croat 2017; 56:566-570 Case Report
10.20471/acc.2017.56.03.26
Acta Clin Croat, Vol. 56, No. 3, 2017566
THE USE OF INFERIOR VENA CAVA FILTERS 
BEFORE SURGERY IN WOMEN 
WITH OVARIAN CANCER WITH THE INITIAL SYMPTOM 
OF DEEP VENOUS THROMBOSIS: 
CASE REPORT AND REVIEW OF LITERATURE
Višnja Nesek Adam1,2, Antonia Bulić1, Aleksandra Jokić1, Nedžad Osmančević1, 
Martina Matolić1 and Gordana Brozović2,3
1Clinical Department of Anesthesiology, Resuscitation and Intensive Care, Sveti Duh University Hospital, Zagreb; 
2School of Medicine, Josip Juraj Strossmayer University, Osijek; 3Department of Anesthesiology and Intensive 
Medicine, University Department for Tumors, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia
SUMMARY – Venous thromboembolism is a frequent complication of gynecologic cancer, and 
may be the fi rst symptom of occult malignant disease. Although anticoagulation therapy remains the 
standard of care in patients presenting with acute venous thromboembolism, inferior vena cava fi lters 
are an important alternative when anticoagulants are contraindicated or ineff ective. We report a case 
of a 69-year-old women who presented with left leg swelling secondary to deep venous thrombosis 
before the diagnosis of ovarian cancer. Th e aim of this study is to review the respective literature and 
report our experience with inferior vena cava fi lter placement to prevent pulmonary embolism in 
 gynecologic cancer patients.
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Introduction
Th e relationship between occult cancer and venous 
thromboembolism (VTE) has been recognized for 
many years. Almost 20% of patients with cancer will 
develop thromboembolic events1, and up to 20% of pa-
tients with thromboembolism have an underlying diag-
nosis of malignancy2. Ovarian cancer has a higher inci-
dence of VTE than other cancers. Because of the high 
incidence of perioperative VTE in women with gyne-
cologic cancer, surgical and anesthesiologic manage-
ment of these patients presents a unique clinical chal-
lenge. Although anticoagulant therapy minimizes the 
risk of recurrence and further VTE, it increases the risk 
of intraoperative bleeding. Also, delaying surgery by 4-6 
weeks due to acute thromboembolism is not advisable 
because delay of cancer treatment may result in its pro-
gression to incurable disease. In order to prevent pulmo-
nary embolism and avoid bleeding from systemic anti-
coagulation in high-risk situations, placement of inferi-
or vena cava fi lters (IVCF) may provide a very attractive 
alternative and optimize the prophylaxis strategy.
We report a case of a 69-year-old patient with 
ovarian cancer presenting preoperatively with femoral 
deep venous thrombosis (DVT) and our experience 
with IVCF placement.
Case Report
A 69-year-old woman presented to our hospital 
with complaints of left leg swelling and feeling tension 
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and discomfort in this leg. She had no signifi cant past 
medical history except for smoking history of 45 ciga-
rettes/day, and she was not taking any medications. 
Th ere was no family history of malignancy.
She also complained of developing a mass in the 
abdomen, which was growing in size for the last two 
months. Physical examination showed a cachectic, fa-
tigued female with pale-gray skin color. Abdominal 
examination revealed a large mass in the lower abdo-
men. Th e left leg was markedly swollen, with edema 
extending from the groin to the foot. Th e skin was fi rm 
and warm to touch, with diff erence in circumference 
of 11 cm from the right thigh. Th e patient was admit-
ted to the Department of Hematology for diagnostic 
testing. Doppler evaluation was performed, and she 
was found to have acute DVT of the left leg that ex-
tended from the left iliofemoral level to the lower leg 
level with extension to the proximal portion of the 
great saphenous vein. Also, color Doppler ultrasonog-
raphy revealed a large tumor mass occupying the whole 
pelvis and abdomen. Th e adjacent inferior vena cava 
and pelvic veins were compressed. Colonoscopy re-
vealed extrinsic compression approximately 30 cm 
from the anocutaneous line.
Pelvic computed tomography scan also revealed a 
large expansive mass. Magnetic resonance imaging 
(MRI) showed a tumor mass of 51x45 mm in size oc-
cupying the ventral part of uterine corpus, and a for-
mation of 38x28 mm with heterogeneous change in 
topography of the left adnexal region. MRI also 
showed an encapsulated cystic mass lesion measuring 
approximately 16x19x11cm seen in the pelvis and ex-
tending cranially up to the lower pole of the right kid-
ney, suggesting a possible ovarian origin.
Th e CEA, CA 125 and CA 19-9 tumor markers 
were measured and found to be signifi cantly elevated.
Th e patient initially received anticoagulant treat-
ment with intravenous heparin, a 5000-unit bolus, fol-
lowed by heparin infusion. Based on the above clinical 
and radiological fi ndings, surgical treatment was indi-
cated, and with due consent, the patient was trans-
ferred to the Clinical Department of Obstetrics and 
Gynecology.
Since heparin therapy has to be stopped at least 6 
hours prior to surgery, and the patient had large tumor 
that occupied the whole pelvis and abdomen, and 
DVT of the left iliofemoral vein, she was considered to 
be at a high risk of developing fatal pulmonary embo-
lism during the perioperative period. Considering the 
tendency of perioperative complications, a multidisci-
plinary approach that involved gynecologists, anesthe-
siologist, hematologists and radiologist resulted in a 
decision to place IVCF. Temporary vena cava fi lter 
(Celect IVC fi lter, Cook Medical, Bloomington, Indi-
ana, USA) was inserted at Clinical Department of Di-
agnostic and Interventional Radiology, Merkur Uni-
versity Hospital, Zagreb (Figs. 1-3). Th e IVCF was 
Fig. 1. Inferior vena cavogram performed prior 
to inferior vena cava fi lter placement.
Fig. 2. Inferior vena cavogram obtained by digital 
subtraction angiography after inferior vena cava 
fi lter placement confi rms appropriate infrarenal 
position of the fi lter.
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inserted via the right internal jugular vein. Th e jugular 
approach is preferable if an iliofemoral thrombus is 
present. Th e procedure was uneventful. Th e next day, 
the patient underwent total abdominal hysterectomy, 
bilateral salpingo-oophorectomy with omentectomy, 
and appendectomy.
Low molecular weight heparin, dalteparin 5000 IU 
sc. was commenced on postoperative day two. Th e 
postoperative course proceeded without any signifi -
cant complications. When the risk of bleeding was 
reduced, the patient was converted to oral warfarin. 
Postoperative histologic examination revealed a clear 
cell carcinoma of the ovary with metastases to the 
omentum. She was discharged home and referred to 
oncology service. She was discharged with recommen-
dations for retrieval of IVCF within the next few 
weeks based on clinical condition and with outpatient 
follow-up at hematology outpatient clinic.
Discussion
Venous thromboembolism such as DVT and pul-
monary thromboembolism is the leading cause of 
death and disability in cancer patients. Th e relation-
ship between cancer and VTE has been recognized 
for many years and was fi rst described by Trousseau in 
18653. Th e incidence rate of VTE in patients with can-
cer is not well established, but is assumed to range 
from 0.5% to 20%, depending on the cancer type, 
background risk, stage of disease, and treatment mo-
dality. Among all malignancies, ovarian cancer is as-
sociated with the highest incidence rates of venous 
thrombosis. Th e diagnosis of VTE, however, may also 
be the fi rst symptom of occult malignant disease and 
has been shown to signifi cantly aff ect overall survival 
in cancer patients4,5. Th e occult tumor types most com-
monly presenting with VTE are cancers of the ovary, 
pancreas and liver6,7.
Ovarian cancer patients most commonly present 
with a pelvic or abdominal mass that may be associat-
ed with ascites, and in 75% of patients with advanced 
stage of disease. Regarding the possible cause of VTE 
in ovarian cancer patients, it is well-known that large 
tumors and/or massive ascites may compress the intra-
pelvic veins, causing a hypercoagulable state and in-
creasing the risk of DVT even before surgery. Massive 
ascites may also increase blood viscosity in blood ves-
sels due to dehydration and inhibition of venous per-
fusion by compressing the inferior vena cava. Th e ne-
cessity of perioperative prevention of VTE is well 
 established and anticoagulation therapy is still the 
mainstay of medical therapy for the treatment and 
prevention of DVT and pulmonary embolism after 
surgery. However, if DVT exists before surgery, anti-
coagulation therapy might be ineff ective or contrain-
dicated, and the primary therapeutic strategy for the 
treatment of this condition is placement of IVCF.
Regarding the indications for IVCF placement, 
there is certain controversy but in general, based on 
recent consensus guidelines, literature review, and cur-
rent practice, widely accepted and validated indica-
tions for IVCF are patients with proven VTE and ab-
solute contraindication for anticoagulation therapy8-10. 
Th is includes patients with active bleeding or coagula-
tion disorder, failure of anticoagulation, and recurrent 
VTE despite conventional treatment, or those who 
had pelvic surgery in the presence of DVT or planned 
major surgery in the near future and had to discon-
tinue anticoagulation therapy before surgery.
Routine placement of IVCF is not indicated in pa-
tients with DVT or pulmonary embolism who can be 
anticoagulated9. Th e use of prophylactic IVCF was re-
viewed by Decousus et al.; they randomized 400 pa-
Fig. 3. Native image confi rming infrarenal 
placement of the inferior vena cava fi lter.
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tients to receive an IVCF with anticoagulation or an-
ticoagulation alone. Vena cava fi lters signifi cantly re-
duced the incidence of pulmonary embolism within 
the fi rst 12 days compared to patients without fi lter, 
but this protection was no longer signifi cant after 2 
years of follow-up. Also, the initial benefi t seen in the 
group of patients with fi lters was overcome by a sig-
nifi cant increase in the rate of recurrent DVT11. Simi-
lar results have been reported from the PREPIC trial, 
a prospective, randomized, controlled study of 400 pa-
tients, which showed that at 8 years, IVCF reduced the 
risk of pulmonary embolism but increased DVT and 
had no eff ect on survival12. Although the use of IVCF 
may be benefi cial in patients at a high risk of pulmo-
nary embolism, systematic use in the general popula-
tion with VTE is not recommended.
Due to the high suspicion of advanced ovarian ma-
lignancy and known DVT, our patient was conse-
quently considered to be at a high risk of developing 
fatal pulmonary embolism. In addition, she had con-
traindication for anticoagulation therapy due to the 
planned major pelvic surgery and risk of serious peri-
operative bleeding. Th erefore, IVCF was preoperative-
ly inserted according to recommendations of the 
American College of Chest Physicians9. Th e basic 
function of IVCF was to prevent the passage of larger 
emboli from the pelvic and lower limb through the in-
ferior vena cava to pulmonary arteries, thus preventing 
pulmonary embolism.
However, despite the marked increase in the use of 
IVCF, it is important to point out that implantation of 
IVCF is not free of complications. Most complications 
and side eff ects may occur during implantation or re-
trieval, and while retained in the body.
During the 2005-2010 period, the Food and Drug 
Administration (FDA) received 921 reports of adverse 
events related to IVCF, of which 328 involved device 
migration, 146 embolizations, 70 perforation of the 
inferior vena cava, 56 involved fi lter fracture, and death 
in 4% of cases. Some of the adverse events may have 
also been related to retrievable fi lters not being re-
moved and staying past the time when the risk of pul-
monary embolism had subsided.
In 2014, the FDA decided that in patients with a 
documented DVT/pulmonary embolism, IVCF should 
be removed between 29 and 54 days after implantation 
in order to avoid these complications, and when thera-
peutic dose of anticoagulation has been reached and 
the patient has been found to tolerate it13.
Th e need of anticoagulation therapy after fi lter 
placement is not yet consensual either, but according 
to the consensus report of the Seventh ACCP Confer-
ence on Antithrombotic and Th rombolytic Th erapy, it 
is recommended that anticoagulation therapy be re-
sumed as soon as possible after fi lter insertion because 
the fi lter alone is not an eff ective treatment of VTE14. 
Our patient was anticoagulated after fi lter placement, 
and anticoagulation was maintained after the procedu-
re as an attempt to minimize VTE recurrence.
In this case report, we presented a patient with a 
large tumor mass occupying the whole pelvis and ab-
domen, and with DVT, in whom IVCF was inserted 
for perioperative prevention of pulmonary embolism. 
It can be concluded that IVCF is a very useful the-
rapeutic device in selected patients at a high risk of 
fatal pulmonary embolism, especially those whose 
 initial thromboembolic event is proven cancer-asso-
ciated DVT.
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Sažetak
UGRADNJA FILTRA U DONJU ŠUPLJU VENU PRIJE OPERACIJSKOG ZAHVATA 
U ŽENE S TUMOROM JAJNIKA I SIMPTOMIMA DUBOKE VENSKE TROMBOZE: 
PRIKAZ SLUČAJA I PREGLED LITERATURE
V. Nesek Adam, A. Bulić, A. Jokić, N. Osmančević, M. Matolić i G. Brozović
Venska tromboembolija je česta komplikacija ginekoloških malignih bolesti, a može se javiti i kao prvi simptom skrivene 
maligne bolesti. Unatoč tome što je antikoagulantna terapija zlatni standard u liječenju bolesnika s akutnom  venskom trom-
boembolijom, postavljanje fi ltra šuplje vene predstavlja značajnu alternativu u bolesnika kod kojih je antikoagulantna tera pija 
kontraindicirana ili neučinkovita. U radu je prikazan slučaj 69-godišnje bolesnice s edemom lijeve noge zbog duboke venske 
tromboze koja je nastala kao prvi simptom karcinoma jajnika. Analizirana je medicinska literatura i opisano naše iskustvo s 
postavljanjem fi ltra šuplje vene u svrhu sprječavanja moguće plućne embolije u bolesnice s karcinomom jajnika.
Ključne riječi: Venska tromboembolija; Filtri šuplje vene; Antikoagulansi – terapijska primjena; Edem; Venska tromboza; Ova-
rijski tumori – komplikacije; Plućna embolija; Prikazi slučaja
